Amgen Inc. (NASDAQ:AMGN) Stake Raised by Transform Wealth LLC

Transform Wealth LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 10.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,354 shares of the medical research company’s stock after acquiring an additional 131 shares during the quarter. Transform Wealth LLC’s holdings in Amgen were worth $353,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Chesley Taft & Associates LLC boosted its holdings in shares of Amgen by 2.0% during the fourth quarter. Chesley Taft & Associates LLC now owns 19,305 shares of the medical research company’s stock worth $5,032,000 after purchasing an additional 383 shares during the period. Clear Harbor Asset Management LLC lifted its position in Amgen by 1.1% in the 4th quarter. Clear Harbor Asset Management LLC now owns 9,371 shares of the medical research company’s stock worth $2,442,000 after buying an additional 104 shares in the last quarter. Lmcg Investments LLC boosted its stake in shares of Amgen by 0.7% during the 4th quarter. Lmcg Investments LLC now owns 37,404 shares of the medical research company’s stock valued at $9,749,000 after buying an additional 257 shares during the period. Solidarity Wealth LLC purchased a new position in shares of Amgen during the 4th quarter valued at $1,098,000. Finally, Crossmark Global Holdings Inc. increased its stake in shares of Amgen by 2.6% in the fourth quarter. Crossmark Global Holdings Inc. now owns 76,607 shares of the medical research company’s stock worth $19,967,000 after acquiring an additional 1,966 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

NASDAQ:AMGN opened at $274.81 on Wednesday. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The stock has a market cap of $147.72 billion, a P/E ratio of 35.19, a PEG ratio of 2.78 and a beta of 0.56. The company has a fifty day moving average price of $272.95 and a 200 day moving average price of $306.92. Amgen Inc. has a one year low of $253.30 and a one year high of $346.85.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 EPS for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. Amgen had a net margin of 13.00% and a return on equity of 168.35%. The business had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. During the same quarter in the prior year, the business earned $4.96 earnings per share. The firm’s revenue for the quarter was up 23.2% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post 19.57 earnings per share for the current year.

Amgen Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a dividend yield of 3.46%. The ex-dividend date is Friday, February 14th. This is a positive change from Amgen’s previous quarterly dividend of $2.25. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Analysts Set New Price Targets

A number of research analysts have commented on AMGN shares. Jefferies Financial Group restated a “buy” rating and issued a $380.00 target price on shares of Amgen in a research note on Tuesday, November 12th. Royal Bank of Canada lowered their price target on Amgen from $360.00 to $330.00 and set an “outperform” rating for the company in a research note on Wednesday, November 27th. Barclays increased their price objective on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. UBS Group reduced their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research note on Thursday, October 31st. Finally, TD Cowen increased their price target on shares of Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $314.91.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.